Newsroom

Takeda Corporate Information

To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/

Media Inquiries

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.

Recent News Releases

October 5, 2022 10/5/2022

U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO^® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

September 14, 2022 9/14/2022

Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn’s Disease

June 22, 2022 6/22/2022

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

April 18, 2022 4/18/2022

Takeda’s TAKHZYRO^® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

February 9, 2022 2/9/2022

Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO^® (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

SEE ALL NEWS AND RELEASES >